GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » Gross Margin %

Celon Pharma (FRA:8RP) Gross Margin % : 64.95% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Celon Pharma's Gross Profit for the three months ended in Sep. 2024 was €7.65 Mil. Celon Pharma's Revenue for the three months ended in Sep. 2024 was €11.77 Mil. Therefore, Celon Pharma's Gross Margin % for the quarter that ended in Sep. 2024 was 64.95%.

Warning Sign:

Celon Pharma SA gross margin has been in long-term decline. The average rate of decline per year is -6.3%.


The historical rank and industry rank for Celon Pharma's Gross Margin % or its related term are showing as below:

FRA:8RP' s Gross Margin % Range Over the Past 10 Years
Min: 58.95   Med: 72.95   Max: 77.88
Current: 64.34


During the past 9 years, the highest Gross Margin % of Celon Pharma was 77.88%. The lowest was 58.95%. And the median was 72.95%.

FRA:8RP's Gross Margin % is ranked better than
77.71% of 969 companies
in the Drug Manufacturers industry
Industry Median: 47.02 vs FRA:8RP: 64.34

Celon Pharma had a gross margin of 64.95% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Celon Pharma was -6.30% per year.


Celon Pharma Gross Margin % Historical Data

The historical data trend for Celon Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma Gross Margin % Chart

Celon Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only 77.16 72.95 63.60 58.95 59.35

Celon Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.58 60.61 62.42 67.85 64.95

Competitive Comparison of Celon Pharma's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Gross Margin % falls into.



Celon Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Celon Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=22.6 / 38.137
=(Revenue - Cost of Goods Sold) / Revenue
=(38.137 - 15.501) / 38.137
=59.35 %

Celon Pharma's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=7.6 / 11.772
=(Revenue - Cost of Goods Sold) / Revenue
=(11.772 - 4.126) / 11.772
=64.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Celon Pharma  (FRA:8RP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Celon Pharma had a gross margin of 64.95% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Celon Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Celon Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Celon Pharma Business Description

Traded in Other Exchanges
Address
Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines